Pacific Biosciences of California, Inc. (NASDAQ: PACB) Stock Competitors & Peer Comparison

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ABT's P/E ratio is 20.69. In terms of profitability, PACB's ROE is -49.62%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ABT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PACB's ROE is -49.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BSX-PA's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SYK has a market cap of 130B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SYK trades at $339.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SYK's P/E ratio is 25.32. In terms of profitability, PACB's ROE is -49.62%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PACB is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SYK's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while MDT trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas MDT's P/E ratio is 15.76. In terms of profitability, PACB's ROE is -49.62%, compared to MDT's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MDT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BSX has a market cap of 73.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BSX trades at $49.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BSX's P/E ratio is 15.91. In terms of profitability, PACB's ROE is -49.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BSX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while EW trades at $89.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas EW's P/E ratio is 33.23. In terms of profitability, PACB's ROE is -49.62%, compared to EW's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PACB.Check EW's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while DXCM trades at $84.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas DXCM's P/E ratio is 36.37. In terms of profitability, PACB's ROE is -49.62%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PACB is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check DXCM's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while RMD trades at $211.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas RMD's P/E ratio is 19.68. In terms of profitability, PACB's ROE is -49.62%, compared to RMD's ROE of +0.24%. Regarding short-term risk, PACB is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for PACB.Check RMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PHG trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PHG's P/E ratio is 15.28. In terms of profitability, PACB's ROE is -49.62%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PHG's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ZBH trades at $96.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ZBH's P/E ratio is 11.38. In terms of profitability, PACB's ROE is -49.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ZBH's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PACB's ROE is -49.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ABMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PEN trades at $324.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PEN's P/E ratio is 84.77. In terms of profitability, PACB's ROE is -49.62%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PEN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SNN trades at $30.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SNN's P/E ratio is 14.16. In terms of profitability, PACB's ROE is -49.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SNN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PACB's ROE is -49.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PACB is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SWAV's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ALGN trades at $173.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ALGN's P/E ratio is 15.83. In terms of profitability, PACB's ROE is -49.62%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, PACB is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for PACB.Check ALGN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while GMED trades at $82.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas GMED's P/E ratio is 18.56. In terms of profitability, PACB's ROE is -49.62%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PACB is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for PACB.Check GMED's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while GKOS trades at $180.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas GKOS's P/E ratio is -209.45. In terms of profitability, PACB's ROE is -49.62%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PACB is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check GKOS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PODD trades at $141.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PODD's P/E ratio is 24.05. In terms of profitability, PACB's ROE is -49.62%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PACB is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check PODD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BIO-B trades at $349.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, PACB's ROE is -49.62%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PACB is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BIO-B's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BIO trades at $352.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BIO's P/E ratio is 38.00. In terms of profitability, PACB's ROE is -49.62%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PACB is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BIO's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas MASI's P/E ratio is 44.43. In terms of profitability, PACB's ROE is -49.62%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PACB is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MASI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BRKR trades at $53.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BRKR's P/E ratio is 26.84. In terms of profitability, PACB's ROE is -49.62%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PACB is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BRKR's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas NARI's P/E ratio is -59.24. In terms of profitability, PACB's ROE is -49.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PACB is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NARI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ITGR trades at $125.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ITGR's P/E ratio is 19.72. In terms of profitability, PACB's ROE is -49.62%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PACB is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ITGR's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while IRTC trades at $127.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas IRTC's P/E ratio is -199.75. In terms of profitability, PACB's ROE is -49.62%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PACB is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for PACB.Check IRTC's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while LIVN trades at $76.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas LIVN's P/E ratio is 18.10. In terms of profitability, PACB's ROE is -49.62%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PACB is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check LIVN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, HAE has a market cap of 4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while HAE trades at $87.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas HAE's P/E ratio is 17.54. In terms of profitability, PACB's ROE is -49.62%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PACB is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HAE's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PACB's ROE is -49.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AXNX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while TMDX trades at $83.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas TMDX's P/E ratio is 42.58. In terms of profitability, PACB's ROE is -49.62%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PACB is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PACB.Check TMDX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AXGN trades at $46.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AXGN's P/E ratio is 122.18. In terms of profitability, PACB's ROE is -49.62%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AXGN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while UFPT trades at $314.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas UFPT's P/E ratio is 32.07. In terms of profitability, PACB's ROE is -49.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PACB is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check UFPT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BFLY trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BFLY's P/E ratio is -36.77. In terms of profitability, PACB's ROE is -49.62%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PACB is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PACB.Check BFLY's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ESTA trades at $77.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ESTA's P/E ratio is -61.44. In terms of profitability, PACB's ROE is -49.62%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PACB is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for PACB.Check ESTA's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PACB's ROE is -49.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PACB is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NUVA's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while NVCR trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas NVCR's P/E ratio is -10.71. In terms of profitability, PACB's ROE is -49.62%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PACB is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for PACB.Check NVCR's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while INSP trades at $60.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas INSP's P/E ratio is 26.51. In terms of profitability, PACB's ROE is -49.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PACB is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INSP's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while TNDM trades at $22.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas TNDM's P/E ratio is -20.35. In terms of profitability, PACB's ROE is -49.62%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PACB is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PACB.Check TNDM's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ENOV trades at $26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ENOV's P/E ratio is 7.62. In terms of profitability, PACB's ROE is -49.62%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PACB is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for PACB.Check ENOV's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CNMD trades at $49.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CNMD's P/E ratio is 10.78. In terms of profitability, PACB's ROE is -49.62%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CNMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ATEC trades at $9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ATEC's P/E ratio is -155.17. In terms of profitability, PACB's ROE is -49.62%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PACB is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ATEC's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while IART trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas IART's P/E ratio is 7.31. In terms of profitability, PACB's ROE is -49.62%, compared to IART's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PACB.Check IART's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AORT trades at $27.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AORT's P/E ratio is 45.28. In terms of profitability, PACB's ROE is -49.62%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PACB is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for PACB.Check AORT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PACB's ROE is -49.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PACB is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HSKA's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while IRMD trades at $92.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas IRMD's P/E ratio is 46.48. In terms of profitability, PACB's ROE is -49.62%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PACB is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check IRMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PACB's ROE is -49.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PACB is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check AVNS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PRCT trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PRCT's P/E ratio is -10.52. In terms of profitability, PACB's ROE is -49.62%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PACB is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for PACB.Check PRCT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SILK's P/E ratio is -18.96. In terms of profitability, PACB's ROE is -49.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PACB is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SILK's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while LMRI trades at $11.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas LMRI's P/E ratio is -22.53. In terms of profitability, PACB's ROE is -49.62%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PACB is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for PACB.Check LMRI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas FNA's P/E ratio is -19.83. In terms of profitability, PACB's ROE is -49.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PACB is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PACB.Check FNA's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BVS trades at $14.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BVS's P/E ratio is 18.59. In terms of profitability, PACB's ROE is -49.62%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PACB is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BVS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, INMD has a market cap of 880M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while INMD trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas INMD's P/E ratio is 10.63. In terms of profitability, PACB's ROE is -49.62%, compared to INMD's ROE of +0.13%. Regarding short-term risk, PACB is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check INMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AVR trades at $8.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AVR's P/E ratio is -4.00. In terms of profitability, PACB's ROE is -49.62%, compared to AVR's ROE of -1.24%. Regarding short-term risk, PACB is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for PACB.Check AVR's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CSII's P/E ratio is -20.83. In terms of profitability, PACB's ROE is -49.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CSII's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SIBN trades at $18.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SIBN's P/E ratio is -54.74. In terms of profitability, PACB's ROE is -49.62%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PACB is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SIBN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while AHCO trades at $5.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas AHCO's P/E ratio is 11.61. In terms of profitability, PACB's ROE is -49.62%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PACB is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for PACB.Check AHCO's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SSII trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SSII's P/E ratio is -73.53. In terms of profitability, PACB's ROE is -49.62%, compared to SSII's ROE of -0.23%. Regarding short-term risk, PACB is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SSII's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BBNX trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BBNX's P/E ratio is -10.53. In terms of profitability, PACB's ROE is -49.62%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PACB is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PACB.Check BBNX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CBLL trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CBLL's P/E ratio is -11.54. In terms of profitability, PACB's ROE is -49.62%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, PACB is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CBLL's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while TCMD trades at $29.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas TCMD's P/E ratio is 33.52. In terms of profitability, PACB's ROE is -49.62%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, PACB is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check TCMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PACB's ROE is -49.62%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PACB is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SRDX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BWAY trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BWAY's P/E ratio is 39.38. In terms of profitability, PACB's ROE is -49.62%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, PACB is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for PACB.Check BWAY's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while KIDS trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas KIDS's P/E ratio is -19.30. In terms of profitability, PACB's ROE is -49.62%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PACB is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PACB.Check KIDS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas APEN's P/E ratio is -9.43. In terms of profitability, PACB's ROE is -49.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PACB.Check APEN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CTKB trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CTKB's P/E ratio is -22.25. In terms of profitability, PACB's ROE is -49.62%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PACB is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CTKB's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PACB's ROE is -49.62%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PACB is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ZIMV's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while VREX trades at $12.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas VREX's P/E ratio is 13.06. In terms of profitability, PACB's ROE is -49.62%, compared to VREX's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check VREX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while DCTH trades at $15.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, PACB's ROE is -49.62%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PACB is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for PACB.Check DCTH's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while NPCE trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas NPCE's P/E ratio is -25.57. In terms of profitability, PACB's ROE is -49.62%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, PACB is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for PACB.Check NPCE's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CERS trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CERS's P/E ratio is -46.91. In terms of profitability, PACB's ROE is -49.62%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PACB is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for PACB.Check CERS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CLPT trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CLPT's P/E ratio is -12.04. In terms of profitability, PACB's ROE is -49.62%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PACB is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CLPT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while OFIX trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas OFIX's P/E ratio is -13.43. In terms of profitability, PACB's ROE is -49.62%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PACB is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check OFIX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SGHT trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SGHT's P/E ratio is -13.34. In terms of profitability, PACB's ROE is -49.62%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PACB is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PACB.Check SGHT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CARL trades at $13.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CARL's P/E ratio is -9.66. In terms of profitability, PACB's ROE is -49.62%, compared to CARL's ROE of -0.38%. Regarding short-term risk, PACB is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CARL's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CV trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CV's P/E ratio is -2.84. In terms of profitability, PACB's ROE is -49.62%, compared to CV's ROE of +1.27%. Regarding short-term risk, PACB is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CV's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PMI trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PMI's P/E ratio is -2.83. In terms of profitability, PACB's ROE is -49.62%, compared to PMI's ROE of +4.99%. Regarding short-term risk, PACB is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for PACB.Check PMI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ELMD trades at $42.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ELMD's P/E ratio is 35.97. In terms of profitability, PACB's ROE is -49.62%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, PACB is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ELMD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while CATX trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas CATX's P/E ratio is -2.13. In terms of profitability, PACB's ROE is -49.62%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PACB is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check CATX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PACB's ROE is -49.62%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PACB is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PACB.Check SMLR's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while TMCI trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas TMCI's P/E ratio is -5.06. In terms of profitability, PACB's ROE is -49.62%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PACB is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for PACB.Check TMCI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while SENS trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas SENS's P/E ratio is -3.51. In terms of profitability, PACB's ROE is -49.62%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PACB is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PACB.Check SENS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ANIK trades at $21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ANIK's P/E ratio is 43.71. In terms of profitability, PACB's ROE is -49.62%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, PACB is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for PACB.Check ANIK's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while PROF trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas PROF's P/E ratio is -5.98. In terms of profitability, PACB's ROE is -49.62%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PACB is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for PACB.Check PROF's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while RXST trades at $6.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas RXST's P/E ratio is -6.73. In terms of profitability, PACB's ROE is -49.62%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PACB is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for PACB.Check RXST's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PACB's ROE is -49.62%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PACB is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PACB.Check MGRM's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while FOCL trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas FOCL's P/E ratio is -8.00. In terms of profitability, PACB's ROE is -49.62%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, PACB is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PACB.Check FOCL's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PACB's ROE is -49.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PACB is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PACB.Check NVRO's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while TLSI trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas TLSI's P/E ratio is -3.34. In terms of profitability, PACB's ROE is -49.62%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PACB is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PACB.Check TLSI's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while RCEL trades at $7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas RCEL's P/E ratio is -4.95. In terms of profitability, PACB's ROE is -49.62%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PACB is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PACB.Check RCEL's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PACB's ROE is -49.62%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PACB is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PACB.Check BSGM's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while QTRX trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas QTRX's P/E ratio is -2.52. In terms of profitability, PACB's ROE is -49.62%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, PACB is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for PACB.Check QTRX's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PACB's ROE is -49.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PACB is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PACB.Check MDGS's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, STIM has a market cap of 165.6M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while STIM trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas STIM's P/E ratio is -4.41. In terms of profitability, PACB's ROE is -49.62%, compared to STIM's ROE of -1.65%. Regarding short-term risk, PACB is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PACB.Check STIM's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while INGN trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas INGN's P/E ratio is -6.65. In terms of profitability, PACB's ROE is -49.62%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PACB is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for PACB.Check INGN's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PACB's ROE is -49.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PACB is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check QIPT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PACB's ROE is -49.62%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PACB is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check ICAD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while OWLT trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas OWLT's P/E ratio is -39.43. In terms of profitability, PACB's ROE is -49.62%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, PACB is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check OWLT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while LUCD trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas LUCD's P/E ratio is -2.61. In terms of profitability, PACB's ROE is -49.62%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, PACB is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for PACB.Check LUCD's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while HSDT trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas HSDT's P/E ratio is -0.02. In terms of profitability, PACB's ROE is -49.62%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, PACB is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HSDT's competition here

Pacific Biosciences of California, Inc. (NASDAQ: PACB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PACB stands at 368.1M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PACB is priced at $1.19 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PACB currently has a P/E ratio of -2.89, whereas HJLI's P/E ratio is N/A. In terms of profitability, PACB's ROE is -49.62%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PACB is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for PACB.Check HJLI's competition here